Ionis Pharmaceuticals
IONS
270 hedge funds and large institutions have $4.46B invested in Ionis Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 87 increasing their positions, 93 reducing their positions, and 58 closing their positions.
17% more call options, than puts
Call options by funds: $73.3M | Put options by funds: $62.6M
0.02% less ownership
Funds ownership: 89.66% → 89.64% (-0.02%)
6% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 93
12% less funds holding
Funds holding: 308 → 270 (-38)
14% less capital invested
Capital invested by funds: $5.2B → $4.46B (-$738M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
53% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$294M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$151M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.5M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$24.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$27M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$26.6M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$22.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$15.7M |
| 5 |
Axa
Paris,
France
|
-$15.3M |
IONS Hedge Fund Activity: Q1 2017 in Review
270 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2017, worth a combined $4.46B — down 14% from $5.2B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of IONS and 27 opened new positions — a net loss of 31 holders — while 93 trimmed existing stakes and 87 added.
The largest buyer was BlackRock, adding an estimated $294M. The largest seller was Baillie Gifford & Co, cutting an estimated $27M.
- 270 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2017, down from 308 in Q4 2016.
- Funds reported $4.46B of Ionis Pharmaceuticals stock for Q1 2017, down 14% quarter-over-quarter.
- 27 funds opened new Ionis Pharmaceuticals positions in Q1 2017 and 58 closed out, a net change of -31 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $294M added.
- The largest Ionis Pharmaceuticals seller in Q1 2017 was Baillie Gifford & Co, an estimated $27M sold.
Based on aggregated 13F filings for Q1 2017.